Adoptive immunotherapy for cancer or viruses

Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9.

Abstract

Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target toxicity. Given recent advances in efficacy in numerous pilot trials, the next steps in clinical development will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.

Publication types

  • Review

MeSH terms

  • Adoptive Transfer
  • Animals
  • Antigens / genetics
  • Antigens / immunology
  • Biomarkers
  • Cell- and Tissue-Based Therapy
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Immunotherapy, Adoptive*
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Receptors, Antigen, T-Cell / immunology
  • Receptors, Antigen, T-Cell / metabolism
  • T-Cell Antigen Receptor Specificity / immunology
  • T-Lymphocyte Subsets / cytology
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • Transduction, Genetic
  • Virus Diseases / genetics
  • Virus Diseases / immunology*
  • Virus Diseases / therapy*

Substances

  • Antigens
  • Biomarkers
  • Receptors, Antigen, T-Cell